Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARS‐CoV‐2 asymptomatic infection: Survey of Infectious Diseases Working Party EBMT

The objective of the study was to assess the current clinical practice and the attitude toward deferral of HCT/chemotherapy in patients with hematological diseases in cases of asymptomatic patients with a positive assay for SARS‐CoV‐2. In August 2021, we performed a survey among EBMT centers regardi...

Full description

Saved in:
Bibliographic Details
Published in:Transplant infectious disease 2022-04, Vol.24 (2), p.e13773-n/a
Main Authors: Styczynski, Jan, Cesaro, Simone, Lilienfeld‐Toal, Marie, Marchesi, Francesco, Gil, Lidia, Mikulska, Malgorzata, Knelange, Nina, Wendel, Lotus, Averbuch, Diana, Camara, Rafael
Format: Article
Language:English
Subjects:
Asymptomatic
Asymptomatic infection
Asymptomatic Infections
Attitudes
Cell therapy
Chemotherapy
Communicable Diseases
COVID-19
deferral
Health services
Hematological diseases
hematopoietic cell transplantation
Humans
Immunotherapy, Adoptive
Infectious diseases
Patients
Polls & surveys
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Stem cell transplantation
Vaccination
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of the study was to assess the current clinical practice and the attitude toward deferral of HCT/chemotherapy in patients with hematological diseases in cases of asymptomatic patients with a positive assay for SARS‐CoV‐2. In August 2021, we performed a survey among EBMT centers regarding their attitude toward deferral of HCT/chemotherapy in patients with a positive PCR result. Centers were willing to defer the planned cellular therapy for patients with asymptomatic SARS‐CoV‐2 infection without previous COVID‐19 disease, and patients who became asymptomatic after a previous COVID19 disease but persistently shed the virus, respectively, in case of high‐risk allo‐HCT (90.2%/76.9%), low‐risk allo‐HCT for malignant diseases (88.2%/83.7%), allo‐HCT for nonmalignant diseases (91.0%/91.0%), auto‐HCT (88.0%/79.8%), and CAR‐T therapy (83.1%/81.4%). The respective rates toward deferral of noncellular therapy patients was lower for both groups of patients, and varied with the primary diagnosis and anti‐malignant treatment. There is a relatively high rate of willingness to defer treatment in asymptomatic patients being positive for SARS‐CoV‐2, planned for cellular therapy, regardless of previous history of vaccination or COVID‐19. The same approach is presented for most of patients before noncellular therapy. Nevertheless, each patient should be considered individually weighting risks and benefits.
ISSN:1398-2273
1399-3062
DOI:10.1111/tid.13773